Determination of dutasteride by LC: Validation and application of the method

被引:8
作者
Kamat, Sudhir S. [1 ]
Choudhari, Vishal B. [1 ]
Vele, Vinayak T. [1 ]
Prabhune, Swarup S. [1 ]
机构
[1] Therapeut Drug Monitoring Lab, Bombay 400022, Maharashtra, India
关键词
column liquid chromatography; dutasteride; selectivity; stability indicating; pharmaceutical preparation;
D O I
10.1365/s10337-008-0602-x
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A simple, rapid, and stability-indicating reversed-phase high-performance liquid chromatographic (LC) method for analysis for dutasteride has been successfully developed. Chromatography was performed on a 150 mm x 4.6 mm C(18) column with acetonitrile-water 60:40 (v/v) as isocratic mobile phase at 1.0 mL min(-1). Ultraviolet detection of dutasteride was at 210 nm. Its retention time was approximately 10 min and its peak was symmetrical. Response was a linear function of concentration over the range 0.2-1 mu g mL(-1) (R(2) = 0.997) and the limits of detection and quantitation were was 0.05 and 0.10 mu g mL(-1), respectively. The method was validated for linearity, precision, repeatability, sensitivity, and selectivity. Selectivity was validated by subjecting dutasteride stock solution to photolytic, acidic, basic, oxidative, and thermal degradation. The peaks from the degradation products did not interfere with that from dutasteride. The method was used to quantify dutasteride in pharmaceutical preparations.
引用
收藏
页码:911 / 916
页数:6
相关论文
共 9 条
[1]  
[Anonymous], 1994, INT C HARM TECHN REQ
[2]  
[Anonymous], 1996, INT C HARM TECHN REQ
[3]   Validation of a population pharmacokinetic/pharmacodynamic model for 5α-reductase inhibitors [J].
Gisleskog, PO ;
Hermann, D ;
Hammarlund-Udenaes, M ;
Karlsson, MO .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1999, 8 (04) :291-299
[4]   The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination [J].
Gisleskog, PO ;
Hermann, G ;
Hammarlund-Udenaes, M ;
Karlsson, MO .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (01) :53-58
[5]  
*GLAXOSMITHKLINE, 2002, AV PRESCR INF
[6]  
GREGORY S, 2006, UROLOGY, V68, P116
[7]   Pharmacogenetic analysis of human steroid 5α reductase type II:: comparison of finasteride and dutasteride [J].
Makridakis, N ;
Reichardt, JKV .
JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2005, 34 (03) :617-623
[8]   Selective and rapid liquid chromatography-tandem mass spectrometry assay of dutasteride in human plasma [J].
Ramakrishna, NVS ;
Vishwottam, KN ;
Puran, S ;
Koteshwara, M ;
Manoj, S ;
Santosh, M .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2004, 809 (01) :117-124
[9]   Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers [J].
Xu, Yi ;
Dalrymple, Susan L. ;
Becker, Robyn E. ;
Denmeade, Samuel R. ;
Isaacs, John T. .
CLINICAL CANCER RESEARCH, 2006, 12 (13) :4072-4079